The essential journal for timely clinical research

Since it was first established in 1974, The Journal of Rheumatology has been publishing forward-thinking, peer-reviewed clinical research in all fields related to rheumatology.

Sign up for alerts, engage in monthly online discussions on our forum, access editorials and articles without subscriptions, read articles published ahead of print, delve into detailed research only available online, and discover dynamic content in unique custom collections.

Forum | Open Access | First Release | Online Supplements | Custom Collections

www.jrheum.org

The Journal of Rheumatology

www.spa-congress.org

Table of Contents

Presidents & Committees ................................................................. 4
Welcome Address ........................................................................ 5
Scientific Programme
  Thursday, October 4 ..................................................................... 6
  Friday, October 5 ......................................................................... 8
  Saturday, October 6 ..................................................................... 11
Poster List
  Poster Session 1 ......................................................................... 13
  Poster Session 2 ......................................................................... 21
  Poster Session 3 ......................................................................... 28
General Information
  Registration .................................................................................. 37
  Social Programme ....................................................................... 39
  General Information ................................................................... 41
  City Map ...................................................................................... 42
  Sponsors .................................................................................... 43
Dear colleagues and friends,

Welcome to the Eleventh International Congress on Spondyloarthritides, taking place on 4 - 6 October 2018 in the beautiful city of Gent.

The congress has grown over the years to become the premier international event in the field of the Spondylarthritides. Indeed, the attendance has almost quadrupled since 1998 to include scientists, medical doctors, allied health professionals, pharmaceutical industry representatives and people affected by these conditions from all over the world.

The success of the Gent congress has been underpinned by the quality of the scientific contributions including the state-of-the-art lectures given by carefully chosen guest speakers and selected abstract presenters.

This year’s programme offers a wide range of topics including basic and clinical translational research, genetics, imaging and therapeutics. A highly regarded part of the meeting are the poster sessions which provide the perfect frame for stimulating and interactive multidisciplinary exchanges among attendees. In addition, and following on from the last edition we have planned a lively debate which promises to be educational as well as entertaining.

New this year is the introduction of the “Gent Oration” aimed to honour a scientist or clinician with an established trajectory in the field which we expect with time, to become one of the main highlights of the congress. It is our great pleasure to invite Professor Joachim Sieper as the inaugural Gent orator in this first edition.

The social programme including the Walking Dinner at the Opening Reception, Gala Dinner and Farewell Reception are sure to give you the opportunity to catch up with old and new friends and enjoy the magic of Gent.

As co-presidents of the 11th International Congress on Spondyloarthritides we would like to welcome you to this exciting occasion which we are sure will once again, provide the best platform for vibrant scientific and clinical discussions in all aspects of these fascinating group of diseases.

Helena Marzo-Ortega & Maxime Breban
Thursday, October 4

13.00  Welcome Address  
Helena Marzo-Ortega & Maxime Breban, Presidents

13.15  INV1  Opening Keynote Lecture  
The role of microbiome in health and chronic inflammation  
Dusko Ehrlich, Jouy-en-Josas, France

SESSION 1:  Tackling the microbiome realm in SpA  
Chairs: Dirk Elewaut & Rubén Burgos-Vargas

14.00  INV2  Innate lymphoid cells at the barrier and inflammation:  
Halt or go?  
Tom Cupedo, Rotterdam, The Netherlands

14.30  INV3  Microbiota in IBD, from inventory to therapeutic intervention  
Harry Sokol, Paris, France

15.00  INV4  Microbiome and gut inflammation in HLA-B27 transgenic rat:  
What is the relationship?  
Robert Colbert, Bethesda, USA

15.30  Coffee Break

SESSION 2:  Do women come from Venus and men from Mars?  
Myths and Truths about gender differences in axial SpA  
Chairs: Irene van der Horst-Bruinsman & Martin Rudwaleit

16.00  INV5  Exploring gender differences in the clinical phenotype and  
response to treatment in axial SpA  
Lianne Gensler, San Francisco, USA

16.30  INV6  So there may be some true after all: What is the underlying  
biology?  
Eric Gracey, Toronto, Canada

17.00  INV7  Painful risk to be female? What we know and why it is not so trivial!  
Walter Magerl, Manheim, Germany

Keynote Lecture - The Gent SpA Oration  
Chairs: Helena Marzo-Ortega & Maxime Breban

17.30  INV8  AS old as time: From bugs to bench to the bedside and back  
Joachim Sieper, Berlin, Germany

18.15  Walking Dinner
SESSION 3: Innate cells and cell signaling in SpA
Chairs: Francesco Ciccia & Robert Inman

08.45  INV9  The importance of unconventional T cells in inflammation and immunity
Dale Godfrey, Melbourne, Australia

09.15  INV10 How macrophages help resolve inflammation
Kodi Ravichandran, Charlottesville, USA & Gent, Belgium

09.45  INV11 Immune effector cells in SpA: What are the pathways?
Paul Bowness, Oxford, UK

10.15  Poster Session 1 and Coffee Break

SESSION 4: The auto-inflammation axis in SpA
Chairs: Atul Deodhar & Jürgen Braun

11.15  INV12 Auto-innmmunity versus auto-inflammation in eye disease in SpA
John Forrester, Aberdeen, UK

11.45  INV13 Auto-antigens as drivers of psoriasis: Increasing specificity and efficacy of treatments in skin and joints
Diamant Thaçi, Lübeck, Germany

SESSION 5: The great debate
Chairs: Filip Van den Bosch & Robert Landewé

12.15  INV14 This house believes that “Treat to target” has no place in the treatment of axSpA
Speaking for: Atul Deodhar, Portland, USA

12.15  INV15 Speaking against: Pedro Machado, London, UK

13.00  Lunch

SESSION 6: HLA-B27: Where are we
Chairs: Robert Colbert & Matthew Brown

14.00  INV16 How peptide loading complex affects MHC class I biology
Simon Trowitzsch, Frankfurt am Main, Germany

14.30  INV17 HLA-B27 and multiomics: Where does it bring us?
Henri-Jean Garchon, Paris, France

15.00  INV18 Is fruit fly relevant to SpA?
Sébastien Gaumer, Paris, France

Selected Oral Presentations I
Chairs: Robert Colbert & Matthew Brown

15.30  O1 Gut dysbiosis in ankylosing spondylitis is associated with increased fecal calprotectin
Eva Klingberg, Sweden

15.40  O2 Inflammasomes activation occurs in the inflamed tissues of AS patients and drives IL-23 expression and ILC3 expansion
Francesco Ciccia, Italy

15.50  O3 Transmembrane TNF signaling through TNF-RI induces SpA-like inflammation, whereas signaling through TNF-RII is crucial for new bone formation
Leonie van Duivenvoorde, The Netherlands

16.00  O4 PROgnostic Markers In axial Spondyloarthritis (PROMISE) – Alpha 1 anti trypsin and beta 2 microglobulin may differentiate ankylosing spondylitis from non radiographic axSpA, mechanical back pain and healthy controls
Elizabeth Reilly, UK

16.10  O5 Impact of gut involvement in early spondyloarthritis - The DESIR cohort
Daniel Wendling, France

16.20  O6 Gender differences in TNFi treatment adherence and response in AS patients: A prospective longitudinal cohort study
Sophie Hoekstra, The Netherlands

16.30  Poster Session 2 and Coffee Break
SESSION 7: Genetics, genomics and SpA: The era of new-sequencing technology
Chairs: John Reveille & Paul Bowness

17.15  INV19  Genetic studies in AS: Progress and translation
Matthew Brown, Brisbane, Australia

17.45  INV20  Lessons from epigenetics for SpA
Julian Knight, Oxford, UK

18.15  INV21  Operation Transformation: The impact of genes and lifestyle in joint disease
Donal O’Shea, Dublin, Ireland

18.45  Scientific Committee Meeting

20.00  Gala Dinner at the Handelsbeurs
For details, see page 39

Selected Oral Presentations II
Chairs: Rik Lories & Percival Sampaio-Barros

08.00  07  Fatty lesions detected on MRI scans in patients with ankylosing spondylitis are based on the deposition of fat in the vertebral bone marrow
Xenofon Baraliakos, Germany

08.07  08  Prevalence of inflammatory and chronic changes suggestive of axial spondyloarthritis in magnetic resonance images of the axial skeleton in individuals < 45 years in the general population as part of a large community study (SHIP)
Xenofon Baraliakos, Germany

08.15  09  Validation of ASAS MRI lesion definitions in axial spondyloarthritis: Data from the Echography in Spondyloarthritis Cohort (ECHOSPA)
Walter Maksymowych, Canada

08.25  10  Inflammation on MRI of spine and sacroiliac joints is highly predictive of structural damage in axial spondyloarthritis: The 5 years data of the DESIR cohort
Alexandre Sepriano, The Netherlands

08.35  11  Dual neutralisation of IL-17A and IL-17F with bimekizumab in patients with active AS: 12-week results from a Phase 2b study
Désirée van der Heijde, The Netherlands

08.45  12  High need for anti-TNF therapy after withdrawal strategy in early peripheral spondyloarthritis
Philippe Carron, Belgium

08.55  13  Dutch recommendations for physical therapy in axial spondyloarthritis (axSpA)
Salima van Weely, The Netherlands
SESSION 8: Bone and SpA: What's new
Chairs: Rik Lories & Percival Sampaio-Barros

09.05 INV22 Role of ectopic BMP signaling in pathologic ossification and angiogenesis
Maurizio Pacifici, Philadelphia, USA

09.35 INV23 Bone control: Gastrointestinal metabolites on a mission...
Georg Schett, Erlangen, Germany

10.05 INV24 Mechanical stress, how does it impact SpA?
Dirk Elewaut, Gent, Belgium

10.35 Poster Session 3 and Coffee Break

SESSION 9: Heterotopic new bone formation in SpA: The plot thickens...
Chairs: Walter Maksymowych & Maria-Antonietta D'Agostino

11.15 INV25 IL-17, TNF and bone formation, what is the evidence?
Pierre Miossec, Lyon, France

11.45 INV26 Is low radiation CT of the spine suitable to assess structural progression in SpA?
Désirée van der Heijde, Leiden, The Netherlands

12.15 INV27 Do we need to bother measuring bone proliferation in axial SpA? Insights from clinical trials
Xenofon Baraliakos, Bochum, Germany

12.45 Closure of the Congress
Helena Marzo-Ortega & Maxime Breban, Presidents

13.00 Farewell Reception

Poster Session 1 is scheduled during the coffee break of 10.15 - 11.15 hrs on Friday, October 5. The presenters of the posters P1 through P58 are requested to be present at their posters.

P1 Which imaging outcomes for axSpA are most sensitive to change? A 5-year analysis of the DESIR cohort

P2 Which scoring method depicts spinal radiographic damage in (early) axial spondyloarthritis best? Five-year results from the DESIR cohort

P3 Spinal radiographic progression in early axial SpA: 5-year data from the DESIR cohort

P4 Correlation between ultrasound nail changes on psoriatic disease and nail psoriasis severity index comparing with rheumatoid arthritis and healthy controls

P5 Progression of structural damage on MRI of the spine and sacroiliac joints in patients with axial spondyloarthritis is limited: The 5-year results in the DESIR cohort

P6 Magnetic resonance imaging of the cervical spine in patients with rheumatoid arthritis and ankylosing spondylitis presenting with chronic neck pain – A systematic comparison of clinical assessments
Baraliakos X., Soltani M., Kiltz U., Braun J. (Germany)
P7  Analysis of the different value of magnetic resonance imaging changes in the sacroiliac joints for a diagnosis of axial spondyloarthritis as judged by rheumatologists and radiologists
Baraliakos X., Ghadir A., Fruth M., Kiltz U., Braun J. (Germany)

P8  Inflammatory lesions and structural changes of sacroiliac joints on MRI in early axial spondyloarthritis: 2-year follow-up study
Rumiantceva D.G., Demina A.B., Erdes S. (Russia)

P10 Diagnostic value of MRI in non-radiographic axial spondyloarthritis

P11 The damage to the hip joints in ankylosing spondylitis according to X-ray examination
Agafonova E.M., Dubinina T.V., Dyomina A.B., Erdes Sh.F. (Russia)

P12 MRI assessment of hip joints involvement in ankylosing spondylitis patients
Agafonova E.M., Dubinina T.V., Dyomina A.B., Erdes S.F. (Russia)

P13 Factors associated with changes in volumetric bone mineral density in patients with ankylosing spondylitis - A five-year prospective study using HRpQCT
Deminger A., Klingberg E., Lorentzon M., Carlsten H., Jacobsson L.T.H., Forsblad-d'Elia H. (Sweden)

P14 The physiological changes of the enthesis in response to age, body mass index and physical activity - An ultrasound study in healthy people
Ureyen S., Solmaz D., Stephenson W., Eder L., Roth J., Aydin S.Z. (Canada)

P15 Optimizing the MRI imaging in patients with inflammatory back pain and suspected Axial Spondyloarthritis
Chan A., Mills T., Yoong P. (UK)

P16 Simple radiographic findings of Achilles tendon in symptomatic and asymptomatic posterior heel in Ankylosing Spondylitis
Sung I.H., Kim T.H., Lee J.K. (Korea)

P17 Diagnostic ascertainment of axial spondyloarthritits in patients presenting with undiagnosed back pain: What is the impact of MRI in rheumatological practice?

P18 MRI lesion definitions in axial spondyloarthritis: A consensus reappraisal from the Assessments in SpondyloArthritis International Society (ASAS)

P19 Ability of magnetic resonance imaging to predict remission and relapse in peripheral spondyloarthritis
Renson T., Carron P., Krabbe S., Jans L., De Craemer A., de Hooge M., Jacques P., Østergaard M., Elewaut D., Van den Bosch F. (Belgium & Denmark)

P20 Clinical evaluation correlates poorly with ultrasound and magnetic resonance imaging of joints and entheses in early peripheral spondyloarthritis
Renson T., Carron P., Krabbe S., Jans L., De Craemer A., de Hooge M., Jacques P., Østergaard M., Elewaut D., Van den Bosch F. (Belgium & Denmark)

P21 Consensus definitions for MRI lesions in the sacroiliac joints of patients with axial spondyloarthritis: First analysis from the assessments in spondyloarthritis international society classification cohort
P22 The contribution of structural MRI lesions to detection of sacroiliitis in patients in the assessments in spondyloarthropathy international society (ASAS) classification cohort

P23 First validation of consensus definitions for MRI lesions in the sacroiliac joint by the assessments in spondyloarthropathy international society (ASAS) MRI group

P24 Which MRI lesions in the sacroiliac joint are associated with the diagnosis of axial spondyloarthropathy after 2 years follow up in the Echography in Spondyloarthritis Cohort (ECHOSPA)?

P25 MRI assessment of bone marrow edema in the sacroiliac joints of patients with spondyloarthropathy: Is the SPAIR T2w technique comparable to STIR?
Dalto V.F., Luppino-Assad R., Crema M.D., Louzada-Junior P., Nogueira-Barbosa M.H. (Brazil & USA)

P26 Validation of a web-based calibration module for the SPARCC MRI SIJ inflammation score based on principles of artificial intelligence

P27 Can sufficient reliability of scoring SIJ structural lesions on MRI be achieved using a web-based calibration module developed on principles of artificial intelligence?

P28 Computer-aided classification of inflammatory sacroiliitis in magnetic resonance imaging

P29 Sacroiliitis in patients with psoriatic arthritis and ankylosing spondylitis - Are there differences?
Luppino-Assad R., de Oliveira R., Nogueira-Barbosa M.H., Louzada-Junior P., Dalto V.F., Sampaio-Barras P.D. (Brazil)

P30 Radiomics association of MRI texture features with spondyloarthritis and sacroiliitis

P31 Spondyloarthritis in a population without access to biologics in 2017 - Padre Hurtado Hospital experience
Ibáñez S., Valenzuela O., Villar M., Silva F., Poblete M., Mogollones K., Mardones C. (Chile)

P32 Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriage with? Results from the worldwide ASAS cohort
P33 Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known? Data from the ASAS, DESIR, and SPACE cohorts

P34 Diagnostic delay in spondyloarthritis: How can we do better?
Resende G.G., Lage R.C., Malheiro O.B., Guimarães D.L., Bomtempo C.A.S., Carvalho M.A.P. (Brazil)

P35 Cardiac conduction disturbances in patients with ankylosing spondylitis – A Swedish longitudinal cohort study

P36 Factors related to health related quality of life in ankylosing spondylitis, overall and stratified by sex

P37 Osteonectin in cardiovascular risk in axial spondyloarthritis: A serological and genetic study

P38 In vivo phosphorylation of p38 in monocytes is enhanced, at the time of diagnosis, in patients with axial spondyloarthritis (axSpA)
Kuuliala A., Kuuliala K., Koivuniemi R., Hämäläinen M., Moilanen E., Kautiainen H., Repo H., Leirisalo-Repo M. (Finland)

P39 Association of IgA antibodies against CD74 with production of IL17A but not of TNFa in patients with active axial spondyloarthritis
Baraliakos X., Kniesz K., Baerlecken N., Braun J., Witte T. (Germany)

P40 Comparison of retention rates between tumor necrosis factor-α inhibitors in ankylosing spondylitis patients: Data from the Korean College of Rheumatology Biologics registry
Kim H.A., Oh S., Park Y.B., Shin K. (South Korea)

P42 Overexpression of macrophage migration inhibitory factor in patients with ankylosing spondylitis and its relation to sex, inflammation and treatment
Kumar A., Do L., Hellman U., Forsblad-d’Elia H. (Sweden)

P43 PROgnostic Markers In axial Spondyloarthritis (PROMISE) – Alpha 1 antitrypsin may identify axSpA patients at risk of uveitis
Reilly E., McGrogan A., Sengupta R. (UK)

P44 Comparing disease status, symptomology, and clinical characteristics of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients in the United States
Deodhar A., Hunter T., Sandoval D., Lobosco S., Moon R., Miligan G. (USA & UK)

P45 Can smoking cause paradoxical findings in patients with psoriatic arthritis?
Kiliç E., Kiliç G., Nas K., Dağlı A.Z., Tekeoğlu I., Kamanli A. (Turkey)

P46 Fatigue, health related quality of life and physiologic status in patients with psoriatic arthritis in remission or low disease activity according to different outcome measures
Kiliç G., Kiliç E., Nas K., Kamanli A., Tekeoglu I. (Turkey)

P47 Fecal calprotectin, a useful biomarker of microscopic bowel inflammation in patients with spondyloarthritis

P48 Undifferentiated spondyloarthritis in Brazilian patients - Predictors of persistent disease compared to remission after eight years of follow-up
da Cruz Lage R., Bomtempo C.A.S., Kakehasi A.M., Carvalho M.A.P., Resende G.G. (Brazil)

P49 Serum miR-214 as a novel noninvasive biomarker for ankylosing spondylitis
Jin S.H., Kook H., Jin H.M., Cho Y.N., Lee S.S., Park Y.W., Kim T.J. (South Korea)
Poster Session 1

P50 Do n-3 polyunsaturated fatty acids affect ECM remodeling in Psoriatic Arthritis?
Sardar S., Kristensen S., Siebuhr A.S., Christensen J.H., Karsdal M.A., Schmidt E.B., Schlemmer A., Bay-Jensen A.C. (Denmark)

P51 Impact of TNF inhibition on work outcomes, in Axial Spondyloarthritis
Shim J., Jones G.T., Pathan E.J., Macfarlane G.J. (UK & Canada)

P52 Patients awareness of the disease treatment, disease activity and spinal mobility monitoring before and after educational schools for rheumatologists and the patients with ankylosing spondylitis

P53 Serum Glucocorticoid-Inducible Kinase-1 (SGK-1) levels in patients with Ankylosing Spondylitis
Keskin G., Inal A., Keskin D., Olmez U. (Turkey)

P54 Use of MRI and biological therapy in incident patients diagnosed as ankylosing spondylitis and spondyloarthritis: Danish nationwide cohort study 2000-2013
Nygaard A., Ljungdalh P., Iachina M., Schiottz-Christensen B. (Denmark)

P55 Disease activity and characteristics of SpA-patients fulfilling ESSG criteria only compared to SpA-patients fulfilling ASAS criteria
Hansen I.M., Bakland G. (Norway)

P56 Serum fibroblast growth factor-23 levels were higher in patients with axial spondyloarthritis and may be associated with disease activity
Gercik O., Coban E., Ozbek Iptec B., Avcioglu G., Solmaz D., Bayindir O., Kabadayi G., Kozaci D., Akar S. (Turkey)

P57 Expression of biomarkers in Psoriatic Arthritis
Juneblad K., Rantapää Dahlqvist S., Alenius G.M. (Sweden)

P58 Association between high body mass index and clinical features of axial spondyloarthritis
Yeo J.N., Seo M.R., Ryu H.J., Choi H.J., Baek H.J. (Republic of Korea)

Poster Session 2

P59 Disease modifying anti rheumatic drugs in the treatment of SAPHO syndrome: Systematic literature analysis
Monet M., Prati C., Guillot X., Sondag M., Verhoeven F., Aubin F., Wendling D. (France)

P60 Treatment outcome with combined methotrexate, sulfasalazine and on-demand NSAIDS in axial spondyloarthritis in a resource-limited real world clinical practice
Ganapati A., Pulukool S., Gowri M., Antonisamy B., Danda D. (India)

P61 Certolizumab pegol in a Spanish cohort of patients with psoriatic arthritis - Preliminary results
Reina D., Mateo L., Prior Á., Laiz A., Moreno M., Juanola X. (Spain)

P62 Evaluation of the work productivity in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients before and after the start of adalimumab therapy in daily practice in Belgium (SpActive Study)
De Clerck L., Maertens M., Remans Ph., Stuer A., Delmotte N., Van den Enden M., Stubbe M. (Belgium)

P63 Canadian observational study assessing the effectiveness of adalimumab vs. non-biologic DMARDs in ankylosing spondylitis (COMPLETE-AS): 12-month data
Bessette L., Khraishi M., Chow A., Pavlova V., Silverberg S., Stewart J., Remple V. (Canada)

P64 Canadian observational study assessing the effectiveness of adalimumab vs. non-biologic DMARDs in psoriatic arthritis (COMPLETE-PsA): 12-month data
Khraishi M., Bessette L., Chow A., Haraoui B., Pavlova V., Stewart J., Remple V. (Canada)

P65 Exploring sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis
Yahya F., Gaffney K., Sengupta R. (UK & Malaysia)

Poster Session 2 is scheduled during the coffee break of 16.30 - 17.15 hrs on Friday, October 5. The presenters of the posters P59 through P112 are requested to be present at their posters.
P66  Efficacy of new treatments on dactylitis of psoriatic arthritis: Update of systematic literature review
Sondag M., Verhoeven F., Guillot X., Prati C., Wendling D. (France)

P68  Comparison of continuous use of NSAIDs and on-demand mode in patients with early axial spondyloarthritis
Erdes S., Rumianteceva D.G., Dubinina T.V., Demina A.B. (Russia)

P69  How to optimize exercise behaviour in axial spondyloarthritis - Results of an intervention mapping study

P70  Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: Results from the 48-week run-in part of C-OPTIMISE
Landewé R., van der Heijde D., Dougados M., Baraliakos X., Van den Bosch F., Hoepken B., Thomas K., Gensler L.S. (The Netherlands, France, Germany, Belgium & USA)

P71  Intravenous golimumab in adult patients with active psoriatic arthritis: Efficacy and safety through 1 Year

P72  Weight-loss improves disease activity in patients with psoriatic arthritis and obesity

P73  A flare of sacroiliitis under Vedolizumab Therapy for Crohn Disease
Sunar İ., Yılmaz G., Yalçın A.P., Ataman Ş. (Turkey)

P74  Predicting persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients
Hunter T., Deodhar A., Bolce R., Schroeder K., Sandoval D. (USA)

P75  Levels of adherence to biologic therapy of spondyloarthritis patients
Madeira N., Cardoso A., Trinca R., Silva C., Santos H., Miguel C., Barcelos F., Medeiros D., Campanilho Marques R., Cunha M. (Portugal)

P76  Secukinumab demonstrates a consistent safety profile over long-term exposure (up to 4 years) in patients with active ankylosing spondylitis - Updated pooled analysis of three phase 3 trials
Deodhar A., Baraliakos X., Marzo-Ortega H., Sieper J., Martin R., Porter B., Shete A. (USA, Germany, UK & Switzerland)

P77  Secukinumab sustains improvements in signs and symptoms in patients with psoriatic arthritis through 2 years (FUTURE 4)

P78  Secukinumab efficacy in psoriatic arthritis patients with or without enthesitis at baseline - Pooled analysis from two Phase-III trials over 2 years
Wallman J. K., Schett G., McInnes I. B., Quebe-Fehling E., Rasouliyan L., Pricop L., Fasth A. E., Gaillez C. (Sweden, Germany, UK, Switzerland, Spain & USA)

P79  Reducing avoidable Biologic drug wastage through collaboration between patients and care providers: The Leeds Spondyloarthritis Service experience
Barr A., Pickles D., Fadl N., Dou J., Vandevelde C., Dubash S., Freeston J.E., Marzo-Ortega H. (UK)

P80  Six-month treatment results for ustekinumab (UST) and TNF inhibitors (TNFi) in psoriatic arthritis (PsA) in Europe (PsABio-Study)

P81  Immune response profiling reveals signaling networks mediating TNF-blocker function and predictors of therapeutic responses in spondyloarthritis patients
Menegatti S., Rouilly V., Latis E., Yahia H., Leloup C., Miceli-Richard C., Dougados M., Bianchi E., Rogge L. (France)

P82  Switching to biosimilars: What have we learned?
Poster Session 2

P83 Monotherapy with biologics vs combined therapy in patients with Psoriatic Arthritis (Psor) peripheral

P84 Is the clinical and therapeutic profile related to satisfactory response to apremilast in psoriatic arthritis?
De la Morena I., Espinosa M., Godoy H., Martínez À., Santos C., Martínez A., Fernández M., Fernández-Llanio N., Palma D., Moreno M.J., Haro A., Conesa A., Calvo J. (Spain)

P85 Impact of biologics on immune cells in Axial Spondyloarthritis
Rosine N., Koturan S., Yahia H., Menegatti S., Leloup C., Bianchi E., Miceli-Richard C., Rogge L. (France)

P86 A cross-sectional evaluation of a Brazilian spondyloarthritis single-center tertiary cohort: Clinical and treatment data
Shimabuco A., de Moraes J.C.B., Sampaio-Barros P., Goldenstein-Schainberg C., Gonçalves C.R., Saad C.G.S. (Brazil)

P87 Personalising care: Using infliximab drug trough and anti-drug antibody levels is a safe and cost effective treatment strategy in Spondyloarthritis

P88 The effect of biologic disease-modifying antirheumatic drugs (bDMARDs) in targeting disease remission in Axial Spondyloarthritis (axSpa): A systematic literature review (SLR)

P89 The GO-DACT protocol: A randomized controlled trial to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy, in improving dactylitis and enthesitis, in MTX naïve psoriatic arthritis patients
Vieira-Sousa E., Canhão H., Fonseca J.E. on behalf of the GO-DACT research team (Portugal)

P90 Tumor necrosis factor inhibitors persistence in psoriatic arthritis patients

P91 Remission rates of biologic-treated spondyloarthritis and psoriatic arthritis patients
Ávila-Ribeiro P., Lourenço-Teixeira R., Fonseca J.E., Vieira-Sousa E. (Portugal)

P92 Dispensation of immunobiologics in model of assisted therapy in the SUS reduces costs with immunobiological in ankylosing spondylitis

P93 Demyelination associated with anti-TNFa treatment in spondyloarthritis patients - A single-center experience
Kougkas N., Vourakis G., Avgoustidis N., Mitsias P.D., Sidiropoulos P., Mastorodemos V.C., Bertisias G. (Greece & USA)

P94 Psoriasis- and inflammatory bowel disease models co-operate with biomechanical stress in triggering mild joint inflammation
Gulino G.R., Van Mechelen M., Lories R. (Belgium)

P95 The JAK1 selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis

P96 mTORC blockade by rapamycin decreases arthritis and spondylitis development and severity in HLA-B27 transgenic rats
Chen S., van Tok M., Pots D., Taurog J., van de Sande M., Baeten D., van Duivenvoorde L. (The Netherlands & USA)
P97 Certolizumab pegol like mice equivalent reduces inflammation and bone damage in transmembrane TNF transgenic mice

P98 Exploring the ankylosing spondylitis-associated regulatory SNPs at the RUNX3 locus
Vecellio M., Cohen C.J., Fischer R., Wordsworth B.P. (UK)

P99 Chronic back pain (CBP) in first degree relatives (FDR's) of patients with ankylosing spondylitis - Predictive value of HLA-B27 and persistence of the inflammatory back pain over time

P100 Intracellular activity of protein phosphatase magnesium-dependent 1A regulates bone metabolism in ankylosing spondylitis
Kim Y.G., Yoo B., Kim T.H., Chang E.J. (Korea)

P101 IL-23 induction of MDL-1+ myeloid cells is critical in the pathogenesis of psoriatic arthritis
Nguyen C.T., Hui D., Kang M., Gu R., Adamopoulos I.E. (USA)

P102 Proteomic and transcriptomic profiling of cells in ankylosing spondylitis patients identifies a novel, synovial-resident CD8+ T cell
Qaiyum Z., Gracey E., Yao Y., Inman R.D. (Canada)

P103 Tyk2 promotes IL-23-induced type 3 immunity and disease progression in spondyloarthritis
Gracey E., Muller M., Miao W., Westlin W., Inman R.D. (Canada, Austria & USA)

P104 MicroRNAs deregulation in monocytes and CD4+ T-lymphocytes from patients with axial spondyloarthritis

P105 Development of a 19-parameter flow cytometry panel to analyze killer immunoglobulin-like receptor (KIR)-expressing lymphocytes in ankylosing spondylitis
Sharma N., Lee J., Ermann J. (USA)

P106 IL-22-expressing but not IL-17A-expressing group 3 innate lymphoid cells are expanded in the inflamed spondyloarthritis joint

P107 Histological evidence that mast cells act as promoters rather than regulators of IL-17A-mediated tissue inflammation in spondyloarthritis

P108 RORyt inhibition selectively targets pathogenic subsets of human iNKT and γδ-T cells enriched in Spondyloarthritis while preserving IL-22 responses
Venken K., Mortier C., Labadia M.E., Jacques P., Decruy T., Coudenys J., Hoyt K., Van Gassen S., Wahle J., Saeyes Y., Van Den Bosch F., Nabozny G., Elewaut D. (Belgium & USA)

P109 Screening for antibody reactivity in early axial spondyloarthritis identifies novel antigenic targets
Quaden D., Vandormael P., Corten K., Vandenabeele F., Vanhoof J., Geusens P., Somers V. (Belgium & The Netherlands)

P110 A probable role of HSP60 in the pathogenesis of spondyloarthritis

P111 An entheseal innate immune cell biological basis for differential efficacy of PDE4 and IL-23 pathway blockade between Psoriatic Disease and Rheumatoid Arthritis

P112 Regulation of cytokine production by iNKT cells requires IRE1a
Poster Session 3 is scheduled during the coffee break of 10.35 - 11.15 hrs on Saturday, October 6. The presenters of the posters P113 through P166 are requested to be present at their posters.

P113  Association of neuropathic-like pain characteristics with clinical and radiographic features in patients with ankylosing spondylitis
Lee K.A., Kim H.R., Lee S.H. (South Korea)

P114  Performance of referral strategies for spondyloarthritis: A population-based nationwide study

P115  Integrated longitudinal analysis increases precision and reduces bias: A comparative 5-year analysis in the DESIR Cohort

P116  High prevalence of axial spondyloarthritis in patients with anterior uveitis and chronic back pain – Preliminary results of the Sp-EYE study
van Bentum R.E., Verbraak F.D., Wolf S., Tan H.S., van der Horst-Bruinsma I.E. (The Netherlands)

P117  Computer tomography defined sacroiliitis in Inflammatory Bowel Disease – A service evaluation of reporting standards
Lim C.S.E., Low B.L.S., Dhillon B., Azegami S., Toms A., Gaffney K. (UK)

P118  Comparison of work disability, depression, and quality of life in ankylosing spondylitis vs psoriatic arthritis: Interim results from the COMPLETE studies
Khraishi M., Bessette L., Harraoui B., Florica B., Setty Y., Teo M., Remple V. (Canada)

P119  Impact of extra-articular manifestations on patient-reported outcomes in ankylosing spondylitis and psoriatic arthritis: Interim results from the COMPLETE studies
Bessette L., Khraishi M., Florica B., Setty Y., Teo M., Remple V. (Canada)

P120  Asas consensus on Spanish nomenclature for spondyloarthritis

P121  Comparison of clinical and imaging arms of the Assessment of Spondyloarthritis International Society (ASAS) classification criteria and parameters of objective inflammation in patients with non-radiographic axial spondyloarthritis (nr-axSpA)

P122  Spinal mobility measures allow discrimination of subgroups of different activity and severity in early axial spondyloarthritis

P123  Measuring spinal mobility over time in early axial spondyloarthritis: Can we do it reliably?

P124  Influence of inflammation and structural damage on global functioning in patients with axial spondyloarthritis - Using the ASAS Health Index in routine care
Kiltz U., Wiatr T., Baraliakos X., Fedorov K., Braun J. (Germany)

P125  Osteoporosis commonly occurs in axial spondyloarthropathy
Fitzgerald G.E., Anachebe T., McCarroll K., O’Shea F. (Ireland)

P126  Syndesmophytes prevent accurate DXA assessment of the spine in axial spondyloarthropathy
Fitzgerald G.E., Anachebe T., McCarroll K., O’Shea F. (Ireland)

P127  Add-on effect of aerobic exercise to stretching in patients with ankylosing spondylitis
Kim H.W., Park J., Kim D., Park J.H., Park M.C. (Korea)
P128  Assessment of early myocardial dysfunction using speckle tracking echocardiography in patients with radiographic and nonradiographic axial spondyloarthritis
Emren V., Gercik O., Ozdemir E., Solmaz D., Gucenmez S., Eren N., Tokac M., Kabadayi G., Akar S. (Turkey)

P129  ASAS, BASDAI and ASDAS remission in secukinumab treated patients with active ankylosing spondylitis: 3-year results from a pooled analysis of two phase 3 studies
Baraliakos X., Van den Bosch F., Machado P., Gensler L., Bintu S., Porter B., Gailliez C., Deodhar A. (Germany, Belgium, UK, USA & Switzerland)

P130  The European Map of Axial Spondyloarthritis (EMAS) - Living with the condition

P132  Assessing functional disability and general health situation in patients with Ankylosing Spondylitis by ASAS health index
Can M. (Turkey)

P133  Empowering Ankylosing Spondylitis (AS) patients through an online personal health system
Eren O., Gençtürk M., Yüksel M. (Turkey)

P134  Prevalence and characterization of psoriatic arthritis mutilans patients from a single tertiary center

P135  The status of health in patients with axial spondyloarthritis (axSpA) as determined by the Assessment of SpondyloArthritis International Society Health Index (ASAS-HI)

P136  Is the delay from recognition of severe active axial spondyloarthritis to biologic disease modifying therapy initiation improving?
Williams T., Wadeley A., Cavill C., Freeth M., Sengupta R. (UK)

P137  Axial spondyloarthropathy-related quality of life improves significantly following initiation of biological disease-modifying therapy
Williams T., Wadeley A., Cavill C., Freeth M., Sengupta R. (UK)

P138  Work productivity among workers with axial spondyloarthritis
Lopes C., Rodrigues-Manica S., Marona J., Mateus M., Pimentel-Santos F., Branco J. (Portugal)

P139  Improvement of cytological grade and tear production in Ankylosing Spondylitis patients under anti-TNF therapy: A long-term follow-up
P140  Emergence of severe spondyloarthropathy related enthesal pathology in Vedolizumab treated Inflammatory Bowel Disease

P141  Patient-acceptable symptom state in psoriatic arthritis: Prevalence and associated factors in real clinical practice
Queiro R., Cañete J.D., Montilla C., Abad M.A., Gómez S., Cábez A. (Spain)

P142  Vitamin D deficiency is associated with greater presence of vertebral fractures, in patients with axial spondyloarthritis
Romera-Lopez C., Fernández-Carballido C., Martinez-Vidal M.P., Pedraz Penalva T., García Moreno M.A. (Spain)

P143  Osteoporosis and vertebral fractures are associated with disease activity and axial radiographic damage in axial spondyloarthritis - 206 Spanish patient’s series
Romera-López C., Fernández-Carballido C., Martínez-Vidal M.P., Pedraz Penalva T., García Moreno M.A. (Spain)

P144  Validity of PROMIS measures in ankylosing spondylitis patients
Hwang M.C., Ogdie A.R., Reveille J.D. (USA)

P145  Patients with axial spondyloarthritis rarely have 1 or 2 inflammatory back pain parameters
de Hooge M., Varkas G., Elewaut D., van den Bosch F. (Belgium)

P147  Diagnostic performance of power Doppler ultrasound of the entheses in patients with uncertain diagnosis of spondyloarthritis: The EchoSpA prospective multicenter French cohort

P149  A study of the HLA-B*27-associated microbiota in healthy individuals reveals intestinal dysbiosis and an altered microbiota-specific immune response may be predisposing events in the pathophysiology of spondyloarthritides

P150  A study of microbial translocation in an animal model of spondyloarthritis
Asquith M., Schleisman M., Davin S., Stauffer P., Karstens L., Rosenbaum J.T. (USA)

P151  The response to TNF-blockers treatment of SpA patients is influenced by the interplay between HLA-B27 and gut microbiota composition at baseline
Vallier M., Dougados M., Ferreira S., Menegatti S., Bianchi E., Rogge L., Chamaillard M., Miceli-Richard C. (France)

P152  Fungi overlooked: The mycobiome as a cause of spondyloarthritis (SpA)
Rosenbaum J.T., Laurence M., Asquith M.J. (USA & Canada)

P153  Specific alterations in the enteric virome in the subclinical gut inflammation of AS patients drive innate immune alterations
Ciccia F., Guggino G., Macaluso F., Rizzo A. (Italy)

P154  Is calprotectin a useful diagnostic tool in diagnosing spondyloarthropathies?
Van Hoovels L., Schiemyck S., Cauchie M., Van Den Breemt S., Vander Cruysen B., Bossuyt X., Stubbe M. (Belgium)

P155  Features of chronic pain syndrome in patients with ankylosing spondylitis
Filatova E.S., Erdes S. (Russia)

P156  Efficiency of long term educational programs for physicians in early diagnosis and treatment of axial spondylarthropathy in Kazan
Lapshina S., Myasoutova L. (Russia)

P157  Preliminary results of development and 12 months follow up test of the mobile application for patients with axial spondyloarthritis
Rumiantceva D.G., Dubinina T.V., Sitalo A.V., Erdes S. (Russia)

P158  Pain beliefs and disability in chronic “inflammatory” and “non-inflammatory” low back pain
Yilmaz Z. (Turkey)

P159  Rapid onset of efficacy in patients with active psoriatic arthritis treated with Ixekizumab: A pooled analysis of data from two phase III clinical trials
Deodhar A., Papp K., Shuler C.L., Park S.Y., Kvien T. (USA, Canada & Norway)
Poster Session 3

P160  Rapid and sustained improvements in both skin and musculoskeletal symptoms correlates with improved quality of life (QoL) in patients with active psoriatic arthritis (PsA)
Kavanaugh A., Birt J., Lin C-Y., Benichou O., Hufford M.M., Gottlieb A.B., Van Beneden K. (USA & Belgium)

P161  Health utility estimates in economic evaluations in axial spondyloarthritis – Different methods, different results

P162  Fibrodysplasia Ossificans Progressiva as a clinical model of new bone formation
Nikishina I., Latypova A., Arsenyeva S., Kaleda M., Alekseev D. (Russia)

P163  Russian Spondyloarthitis assessment groups' definition and criteria of remission in Axial Spondyloarthritis

P164  Assessment of lumbar spinal mobility using inertial measurement units in axial spondyloarthritis
Franco L., Ward W., Sengupta R., Cazzola D. (UK)

P165  The prevalence of rheumatological diseases and psoriasis in the first-degree relatives of PsA patients
Nas K., Çevik R., Dağlı A.Z., Tekeoğlu I., Kamanli A., Sağ S. (Turkey)

P166  Association of work instability with fatigue and emotional status in patients with ankylosing spondylitis - Comparison with healthy controls
Ulus Y., Akyo, Y., Bilgici A., Kuru O. (Turkey)
Registration

As of 15/09/’18

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participant MD</td>
<td>€ 700,00</td>
</tr>
<tr>
<td>Researcher Non-MD with Abstract*</td>
<td>€ 400,00</td>
</tr>
<tr>
<td>Student with Abstract*</td>
<td>€ 400,00</td>
</tr>
<tr>
<td>Industry Participant</td>
<td>€ 900,00</td>
</tr>
<tr>
<td>Gala Dinner on Friday, October 5**</td>
<td>€ 75,00</td>
</tr>
</tbody>
</table>

*Presenting author only
**If seats are available

The registration includes
The registration fee includes access to all lectures, to the Opening Reception and Walking Dinner, the lunches, coffee breaks and the Farewell Reception as indicated in the programme. Participants also have free access to the exhibition.
Participation into the Opening Reception & Walking Dinner and the Farewell Reception is free but pre-registration is mandatory.
Separate registration and payment is required to participate in the Gala Dinner.

Payment
Payment is to be made by credit card. All major credit cards are accepted.

Cancellations
Cancellations received no later than August 31, 2018, entitle registered persons to a 50% refund. In order to cancel your registration and/or hotel booking please contact Laurence Schepens: laurence@medicongress.com.

Leading and Innovating in axSpA

Addressing key unmet needs...

...through innovative clinical study designs...

...and advancing the understanding of the role of IL-17 family of cytokines in immune-inflammatory conditions

Visit us at the UCB booth # 1 to find out more
Social Programme

Opening Reception and Walking Dinner on Thursday, October 4
This Opening Reception and Walking Dinner will take place at Opera Gent and is included in the registration fee. Pre-registration however is required.

Gala Dinner on Friday, October 5
The Gala Dinner will take place at the ‘Handelsbeurs’, an impressive building with a commanding façade.

The Handelsbeurs is located on the Kouter square, well-known for its 19th century stately buildings and for its flower market on Sundays. The Handelsbeurs is located at a mere stone’s throw from Opera Gent.

Separate registration and payment is required to participate in the Gala Dinner.

Farewell Reception on Saturday, October 6
The Farewell Reception will take place at Opera Gent and is included in the registration fee. Pre-registration however is required.
Come to the Janssen R&D booth!

You can learn more about the Janssen programme in rheumatology

Location: Foyer of the Opera House

Venue
Opera Gent
Schouwburgstraat 3, 9000 Gent
https://operaballet.be/en

Opera Gent is located in the city centre, within walking distance from the hotels.

It is strictly forbidden to take drinks/food into the meeting room.

Date
Thursday, October 4 - Saturday, October 6, 2018

Language
The official congress language is English.

Exhibition
A medical exhibition is held on the occasion of the Congress and is located on the 2nd floor. Access is free for registered participants. The exhibition is not accessible for non-MDs.

Catering
Coffee breaks and lunches will be served in the exhibition area located on the 2nd floor.

WiFi
Free WiFi is offered to all participants and exhibitors. The WiFi access code will be available on-site.

Liability
Neither the organisers nor Medicongress accept liability for damages and/or losses of any kind which may be incurred by Congress participants during the Congress. Participants are advised to take out insurance against loss, accidents or damage which could be incurred during the Congress.

Organisation and Administration
MEDICONGRESS
Noorwegenstraat 49
B-9940 Evergem, Belgium
Phone: +32 (0)9 218 85 85
Fax: +32 (0)9 344 40 10
Email: congresses@medicongress.com

Programme developed in collaboration with Wonder Reizen, Lic. A 5603
Novartis: Supporting the rheumatology community to improve patients’ lives

- Initiating non-interventional studies
- Collaborating with national registries
- Cooperating with the rheumatology community to better understand remission
- Introducing innovation and technology into our clinical trial designs
- Supporting medical education initiatives
- Partnering to further understand the basic research needs of disease
- Launching imaging preceptorship programs (e.g., PsA Advances in Imaging & Clinical Evaluation)